<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03899883</url>
  </required_header>
  <id_info>
    <org_study_id>18-1700</org_study_id>
    <nct_id>NCT03899883</nct_id>
  </id_info>
  <brief_title>Uric Acid Lowering Trial in Youth Onset T2D</brief_title>
  <acronym>ULTRA-T2D</acronym>
  <official_title>ULTRA-T2D Study: Uric Acid Lowering Trial in Youth Onset T2D</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado Denver School of Medicine Barbara Davis Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado Denver School of Medicine Barbara Davis Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adolescents and young adults with youth-onset type 2 diabetes (T2D) are disproportionally
      impacted by hyperuricemia compared to non-diabetic peers and youth with type 1 diabetes
      (T1D). In fact, 50% of males with youth-onset T2D have serum uric acid (SUA) greater than 6.8
      mg/dl. The investigators also recently demonstrated that higher SUA conferred greater odds of
      developing hypertension and diabetic kidney disease (DKD) in youth with T2D over 7 years
      follow-up. Elevated SUA is thought to lead to cardiovascular disease (CVD) and DKD by
      inflammation, mitochondrial dysfunction and deleterious effects on nephron mass. While there
      are studies demonstrating beneficial effects of uric acid (UA) lowering on vascular health in
      the general population, there are no studies in youth-onset T2D. Youth-onset T2D carries a
      greater risk of DKD and CVD compared to adult-onset T2D and T1D.

      Accordingly, a clinical trial evaluating UA lowering therapies is needed in youth-onset T2D.
      Krystexxa (pegloticase), a uricase, effectively lowers SUA and therefore holds promise as a
      novel therapy to impede the development of CVD and DKD in youth-onset T2D. This proposal
      describes a pilot and feasibility trial evaluating the effect of UA lowering by pegloticase
      on markers of CVD and DKD in ten (n=10) youth aged 18-25 with youth-onset T2D (diagnosed &lt;21
      years of age) over 7 days. The overarching hypothesis is that pegloticase improves marker of
      cardiorenal health by lowering UA.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiovascular Markers</measure>
    <time_frame>5 min</time_frame>
    <description>Measured by Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP), Mean Arterial Pressure (MAP)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulse Wave Velocity (PWV)</measure>
    <time_frame>2 hours (x2 study visits)</time_frame>
    <description>Measured by Aortic MRI renal MRI (4D Flow)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Wall Shear Stress (WSS)</measure>
    <time_frame>2 hours (x2 study visits)</time_frame>
    <description>Measured by Aortic MRI renal MRI (4D Flow)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal Blood Flow</measure>
    <time_frame>1 hour (x2 study visits)</time_frame>
    <description>Measured by 4D Flow renal MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glomerular Filtration Rate</measure>
    <time_frame>4 hours (x2 study visits)</time_frame>
    <description>Measured by Iohexol Clearance in Plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Albumin Excretion Rate (AER)</measure>
    <time_frame>4 hours (x2 study visits)</time_frame>
    <description>Measured by albumin and creatinine concentrations in urine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Calculated parameters of intrarenal hemodynamic function</measure>
    <time_frame>1 hour</time_frame>
    <description>Measured by using existing renal hemodynamic calculations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum uric acid (sUA)</measure>
    <time_frame>1 hour</time_frame>
    <description>Measured by baseline sUA compared to sUA one week later</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Diabetic Kidney Disease</condition>
  <condition>Hyperuricemia</condition>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Type2 Diabetes</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Diabetic Nephropathies</condition>
  <condition>Diabetes Complications</condition>
  <arm_group>
    <arm_group_label>Pegloticase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration of pegloticase (8 mg IV in 250 mL 0.9% normal saline)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegloticase 8 MG/ML [Krystexxa]</intervention_name>
    <description>One time dosing of pegloticase will be administered. Participants will receive an infusion of pegloticase over two hours in the outpatient clinical and translational research center (CTRC) at Children's Hospital Colorado, and will be monitored after infusion.</description>
    <arm_group_label>Pegloticase</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men

          -  Ages 18-25

          -  Youth-onset T2D (diagnosis &lt;21 years)

          -  serum uric acid ≥ 5 mg/dl

        Exclusion Criteria:

          -  Glucose-6-phosphate (G6P) deficiency

          -  Allergies to seafood or iodine

          -  MRI contraindications (severe claustrophobia, non-MRI compatible implantable devices,
             weight ≥ 450 lbs)

          -  HbA1C ≥ 12%

          -  Recent (1 month prior) diagnosis of diabetic ketoacidosis (DKA) or hyperosmolar
             hyperglycemia

          -  Congestive heart failure

          -  History of multiple and/or severe allergies or anaphylactic reactions

          -  Uric acid lowering medications (ie: allopurinol, febuxostat)

          -  Pegvisomant, pegvaliase, peginterferon alfa 2b, peginterferon alfa 2a, pegfilgrastim,
             pegaspargase, pegaptanib, pegademase and certolizumab pegol

          -  Participation in another investigational study within 2 weeks prior to study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Amy Rydin, MD</last_name>
    <phone>720-777-2560</phone>
    <email>amy.rydin@childrenscolorado.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carissa Vinovskis, MS</last_name>
    <phone>720-777-2660</phone>
    <email>carissa.vinovskis@childrenscolorado.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Rydin, MD</last_name>
      <phone>720-777-2560</phone>
      <email>amy.rydin@childrenscolorado.org</email>
    </contact>
    <contact_backup>
      <last_name>Carissa Vinovskis, MS</last_name>
      <phone>720-777-2660</phone>
      <email>carissa.vinovskis@childrenscolorado.org</email>
    </contact_backup>
    <investigator>
      <last_name>Amy Rydin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 28, 2019</study_first_submitted>
  <study_first_submitted_qc>March 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2019</study_first_posted>
  <last_update_submitted>March 20, 2020</last_update_submitted>
  <last_update_submitted_qc>March 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Colorado Denver School of Medicine Barbara Davis Center</investigator_affiliation>
    <investigator_full_name>Petter Bjornstad</investigator_full_name>
    <investigator_title>Assistant Professor; Department of Medicine, Division of Pediatrics &amp; Nephrology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Diabetes Complications</mesh_term>
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

